Otezla (apremilast) works by blocking an enzyme called PDE4 inside your immune cells, which raises levels of a natural signaling molecule that dials down inflammation. Unlike biologics that target a single protein outside the cell, Otezla works inside cells to shift the overall balance between inflammatory and anti-inflammatory signals. It’s taken as a pill twice daily and is approved for plaque psoriasis, psoriatic arthritis, and oral ulcers from Behçet’s disease.
The PDE4 Pathway
Your immune cells contain an enzyme called phosphodiesterase 4, or PDE4. Under normal conditions, PDE4 breaks down a molecule called cAMP, which acts as a chemical messenger that helps regulate inflammation. When PDE4 is overactive, cAMP levels drop too low, and the cell ramps up production of proteins that drive inflammation.
Otezla blocks PDE4, allowing cAMP to build up inside the cell. Higher cAMP levels trigger a cascade that reduces several key inflammatory proteins, including TNF-alpha, IL-23, IL-17A, IL-17F, and IL-22. These are some of the same proteins targeted by injectable biologics, but Otezla suppresses them through a different route. At the same time, elevated cAMP boosts production of IL-10, an anti-inflammatory protein. The net effect is a broad rebalancing: less inflammation driving skin plaques or joint damage, more signals calming the immune response down.
PDE4 isn’t only found in immune cells. It’s also expressed in keratinocytes, the skin cells that multiply too rapidly in psoriasis. By inhibiting PDE4 in those cells directly, Otezla may address both the immune overreaction and the skin cell overgrowth that produce psoriatic plaques.
What It Treats
The FDA has approved Otezla for three conditions. It can treat plaque psoriasis in adults who are candidates for light therapy or systemic treatment, and in children aged 6 and older who weigh at least 20 kg (about 44 pounds) with moderate to severe disease. It’s also approved for active psoriatic arthritis in adults and for oral ulcers associated with Behçet’s disease in adults.
How Quickly It Works
Some people notice improvement within the first few weeks, but the full effect typically takes 12 to 16 weeks to develop. In clinical trials for psoriasis, results were measured at the 16-week mark. About 33 to 41 percent of patients on the standard dose achieved a 75 percent reduction in their psoriasis severity score at that point, compared to roughly 6 percent on placebo. That response rate is lower than what injectable biologics achieve, which is one reason Otezla is often positioned as a first-line systemic option before stepping up to stronger treatments.
For Behçet’s disease, pain relief from oral ulcers began as early as two weeks into treatment.
The Starter Pack and Dosing
Otezla uses a 5-day ramp-up schedule to ease your body into the medication and reduce stomach-related side effects. On day one, you take just 10 mg in the morning. Each day, the dose increases slightly: by day four you’re at 20 mg twice daily, and by day six you reach the full maintenance dose of 30 mg twice daily. Your pharmacy will typically dispense a starter pack with the doses clearly labeled for each time slot.
This gradual titration matters because the most common side effects are gastrointestinal, and jumping straight to the full dose makes them worse.
Common Side Effects
Nausea and diarrhea are the most frequent complaints. In psoriasis trials, about 17 percent of patients experienced each of these, compared to 6 to 7 percent on placebo. Most of these episodes occurred within the first few weeks and tended to settle as the body adjusted. The rates are higher in Behçet’s disease trials, where diarrhea affected about 41 percent of patients, likely reflecting the higher sensitivity of that population.
Weight loss is another effect worth knowing about. A Penn Medicine study found that patients on Otezla lost an average of 5 to 6 percent of their subcutaneous and visceral fat, emerging around four months into treatment and persisting for at least a year. For some people this is a welcome side effect; for others, especially those already underweight, it’s something to monitor.
Depression and Mood Changes
The FDA label carries a warning linking Otezla to an increased incidence of depression. If you have a history of depression or suicidal thoughts, that risk-benefit conversation is especially important before starting. Anyone taking Otezla should watch for new or worsening mood changes, and family members or caregivers should be aware of this possibility too.
Drug Interactions
Otezla is broken down by liver enzymes. Medications that strongly activate those enzymes can clear Otezla from your system too quickly, reducing its effectiveness. In one study, the seizure medication rifampin reduced the amount of Otezla in the bloodstream by 72 percent. Other drugs in this category include phenobarbital, carbamazepine, and phenytoin. Using Otezla alongside any of these is not recommended.
On the positive side, Otezla has a relatively clean interaction profile compared to many other systemic treatments for psoriasis. It does not require routine blood work or liver function monitoring, which is one of the practical advantages over older oral medications like methotrexate.
How It Compares to Biologics
Biologics are injected or infused proteins that block a single inflammatory target outside the cell, such as TNF-alpha or IL-17. Otezla works upstream of those targets, inside the cell, modulating multiple inflammatory and anti-inflammatory pathways simultaneously. This broader but less potent mechanism means Otezla generally produces more modest skin clearance than the newest biologics, but it also comes with a different safety profile: no immunosuppression-related risks like serious infections or required tuberculosis screening.
For many people with moderate psoriasis or psoriatic arthritis, Otezla offers a meaningful improvement with the convenience of a pill and fewer monitoring requirements. For those with severe disease who don’t respond adequately, biologics remain the next step up.